Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: No heparin Clear all
Terminated Phase 3 Interventional Results available

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
dalteparin injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Sacramento, California • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients

NCT02412982
View directory record Official record
Conditions
Traumatic Injury, Venous Thromboembolism
Interventions
Enoxaparin 40 mg q12h, Enoxaparin 30 mg q8h
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Thrombelastography Based Dosing of Enoxaparin

NCT00990236
View directory record Official record
Conditions
Thromboembolic Complications
Interventions
Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2Phase 3 Interventional

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

NCT04372589
View directory record Official record
Conditions
COVID-19, Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Jefferson, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

NCT01076764
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
13,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 10, 2026, 4:40 PM EDT
Recruiting Not applicable Interventional

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

NCT05879835
View directory record Official record
Conditions
Pediatric Intestinal Failure
Interventions
KiteLock 4% Sterile Catheter Lock Solution, Heparin Lock Solution
Device
Lead sponsor
SterileCare Inc.
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Boston, Massachusetts • Omaha, Nebraska • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Intranasal Heparin Tolerability Study

NCT04490239
View directory record Official record
Conditions
Covid19
Interventions
Intranasal heparin sodium (porcine)
Drug
Lead sponsor
Joshua Sharp
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

NCT06004674
View directory record Official record
Conditions
Adverse Pregnancy Outcome
Interventions
Lovenox 40mg
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional

A-priori Versus Provisional Heparin on Radial Artery Occlusion After Transradial Coronary Angiography and Patent Hemostasis

NCT01489917
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Patent hemostasis and heparin
Other
Lead sponsor
Olivier F. Bertrand
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery

NCT00718224
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 10, 2026, 4:40 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Clinical Performance of the Investigational GEM Hemochron® 100 in Populations Ages 18 Years and Older

NCT03074266
View directory record Official record
Conditions
Blood Coagulation Test
Interventions
GEM Hemochron 100 ACT
Diagnostic Test
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 10, 2026, 4:40 PM EDT
Not yet recruiting Phase 3 Interventional

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

NCT06628778
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Enoxaparin
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2035
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?

NCT05021263
View directory record Official record
Conditions
Colo-rectal Cancer, Anesthesia
Interventions
IV Medications, placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

NCT03003390
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 4 Interventional Results available

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

NCT01246011
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Presence of Heparin/Platelet Factor 4 Antibody
Interventions
Argatroban and warfarin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

NCT06118957
View directory record Official record
Conditions
Thromboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Assessment of Acute Disease to Reduce Imaging Costs

NCT01059500
View directory record Official record
Conditions
Acute Coronary Syndrome, Pulmonary Embolism
Interventions
Webtool
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 99 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Jackson, Mississippi • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

NCT04357730
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
Interventions
Alteplase 50 MG [Activase]
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 10, 2026, 4:40 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Wet Heparinized Suction for Abdominal Cancer

NCT05041335
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus, Cancer of Liver, Cancer
Interventions
wet heparinzed suction, Microsieve, No heparin flush, No microsieve
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Not applicable Interventional Results available

Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

NCT03465735
View directory record Official record
Conditions
Acute DVT of Lower Extremity
Interventions
Vascular Boot, Standard of Care
Combination Product · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Comparison of Two Pulmonary Embolism Treatments

NCT05684796
View directory record Official record
Conditions
Pulmonary Embolism Acute
Interventions
Anticoagulation, mechanical aspiration thrombectomy
Drug · Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Enoxaparin Metabolism in Reconstructive Surgery Patients

NCT02411292
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus, Reconstructive Surgery
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

NCT04042324
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic, Heparin
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 10, 2026, 4:40 PM EDT